The effects of active hexose correlated compound (AHCC) on level of CD4+ and CD8+ in epithelial ovarian cancer patients receiving platinum based chemotherapy

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20141119001

Enrollment

Registered

2014-11-19

Start date

2014-04-24

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD4 and CD8 level in ovarian cancer patients receiving platinum base chemotherapy

Interventions

2 capsules tid pc until complete chemotherapy 6 courses,2 capsules tid pc until complete chemotherapy 6 courses

Active Comparator Dietary Supplement,Placebo Comparator Other

AHCC,Placebo

Eligibility

Sex/Gender

Female

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: - First line chemotherapy - Age between 20-70 years - No underlying disease such as HIV infection SLE, leukemia ( low immune ) - Liver function within normal limit - Kidney function within normal limit - No steroid used

Exclusion criteria

Exclusion criteria: - History of radiation before or at time of receiving chemotherapy - ECOG performance status more than 2 - Bone marrow metastasis

Design outcomes

Primary

Measure	Time frame
Compare CD4 & CD8 level between AHCC & placebo before CMT, after CMT course 1, 3 & 6 CD4 & CD8 level	—

Secondary

Measure	Time frame
Compare bone marrow suppression, QOL between AHCC & placebo Before CMT & after CMT every course CBC, FACT-G,Compare side effect between AHCC & placebo Before CMT & after CMT every course Clinical	—

Countries

Thailand

Contacts

Public ContactWineeya Suknikhom

King Chulalongkorn Memorial hospital

pearlwineeya@gmail.com0815637446

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026